Unlike established compounds with decades of clinical data, optimal dosing remains uncertain
After final selection, data were extracted by three investigators (XX, PPZ, and CXF) from the eligible case reports, which included first authors name, year of publication, country, patient sex and age, medical history, indication for medication, route of administration, dosage, concomitant medications, ADRs, diagnosis, time to ADR onset, clinical presentation, drug re-exposure, intervention measures, laboratory parameters, such as blood urea nitrogen (BUN), serum creatinine (SCr), estimated glomerular filtration rate (eGFR), urine protein-to-creatinine ratio (UPCR), and proteinuria, and patient outcomes
A 2021 study from Denmark looked at the medical records of people who had both IBD and type 2 diabetes
In a 2023 phase 2 trial published in the New England Journal of Medicine, adults with obesity on the highest dose lost an average of 24.2 percent of their body weight over 48 weeks